Astellas’ Xospata wins AML approval, with Daiichi close behind by Angus Liu Thursday, November 29, 2018 Astellas will likely soon be joined by Daiichi in relapsed/refractory FLT3-mutated AML, and both have eyes on Novartis' Rydapt.
NICE issues early 'no' on RoActemra, Rydapt by Carly Helfand Wednesday, December 6, 2017 Two Swiss pharma giants got some news out of England Tuesday that they weren’t too excited about.
Novartis wins FDA nod for Rydapt, new targeted drug for AML by Eric Palmer Friday, April 28, 2017 Novartis got FDA approval today for Rydapt, its new breakthrough treatment for acute myeloid leukemia (AML), which is expected to generate more than $250 million in annual sales in the next few years.
